
BPIQ-I

MedChemExpress

Cat. No.:	HY-112405	
CAS No.:	174709-30-9	
Molecular Formula:	C ₁₆ H ₁₂ BrN ₅	HN
Molecular Weight:	354.2	
Target:	EGFR	N
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK	ĺ
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	N



Product Data Sheet

Inhibitors

•

BIOLOGICAL ACTIVITY				
Description	BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor BPIQ-I shows anti-proliferative actively [1][2].			
In Vitro	BPIQ-I (0-50 μM; 3 days) shows antiproliferative activity with EC ₅₀ s of >50, 30, >50, 6.5, >50 μM for A-431, MDA-MB-468, U-87, SKOV-3, MDAMB-231 cells, respectively ^[1] . BPIQ-I (10 nM) blocks erbB RTKs by competing with ATP, eliminating the CO2 sensitivity ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]			
	Cell Line:	A-431, MDA-MB-468, U-87, SKOV-3, MDAMB-231 cells		
	Concentration:	0-50 μΜ		
	Incubation Time:	3 days		
	Result:	Inhibited cells growth with $EC_{50}s$ of >50, 30, >50, 6.5, >50 μM for A-431, MDA-MB-468, U-87, SKOV-3, MDAMB-231 cells, respectively.		

REFERENCES

[1]. Rae JM, et al. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat. 2004 Jan;83(2):99-107.

[2]. Zhou Y, et al. Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules. Am J Physiol Renal Physiol. 2006 Aug;291(2):F358-67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA